Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.
Products, services, technology
META10-19 CAR-T achieved 100% CR at 1/1000th standard dose in early hematology/SLE trials—unprecedented efficacy with enhanced safety. META10-TILs (solid tumors) and META10-BCMA (myeloma) trials initiated; in vivo CAR-T, solid tumor CAR-T, and automated production system in preclinical development.
Cooperation possibilities
Licensing and co-development partnerships in:
- Hematologic malignancies
- Solid tumors
- Systemic lupus erythematosus (SLE)
- In vivo CAR-T platform
We are also open to strategic investment and fundraising opportunities to accelerate clinical development and global access.
Some insights
We make a difference by developing innovative cutting-edge cancer immunotherapies with the potential to cure solid tumors and strive to improve the quality of life for patients and their families.
We are the only known metabolic immunotherapy company to integrate the most advanced technologies like artificial intelligence, genome editing, metabolic immunoengineering to overcome T cell exhaustion - a major bottleneck of T-cell immunotherapy.
Our team combines breakthrough innovation in metabolic immunoengineering, world-class translational research, high-efficiency development, and relentless determination to deliver durable, accessible cures that truly benefit patients.
Networking opportunities
Investors, scientific collaborators, pharmaceutical companies interested in partnering
